Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Robert L. Ray who wrote (22822)	6/29/1998 12:40:00 PM
From: Mudcat	Respond to of 32384

<I am curious what drugs, in your perception, have been kept off the market to the detriment of the public?> Well if you believe what is written on this thread, then the FDA delaying Ontak for some administrative reason certainly falls under the category of detrimental to people who are suffering from KS or CTCL.

To: Robert L. Ray who wrote (22822)	6/30/1998 1:03:00 AM
From: DMB	1 Recommendation Respond to of 32384

Robert, I have often heard the FDA criticized (bashed?) for being too slow to approve new drugs. Thank you for your example. I claim a large portion of ignorance when it comes to issues regarding generic estrogens. In my own area of expertise, I am a medical oncologist, I have found the FDA to be pretty responsive. I have felt that the assertion that people are dying unnecessarily because of unapproved drugs to be a bit off base. However, I am willing to listen to other points of view. DMB